Mammographic Image Based Breast Tissue Classification with Kernel Self-optimized Fisher Discriminant for Breast Cancer Diagnosis

2011 ◽  
Vol 36 (4) ◽  
pp. 2235-2244 ◽  
Author(s):  
Jun-Bao Li
2021 ◽  
pp. 313-320
Author(s):  
Shaila Chugh ◽  
Sachin Goyal ◽  
Anjana Pandey ◽  
Sunil Joshi ◽  
Mukesh Azad

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6531-6531 ◽  
Author(s):  
Kathryn Jean Ruddy ◽  
Lindsey R. Sangaralingham ◽  
Heather B. Neuman ◽  
Caprice Christian Greenberg ◽  
Rachel A. Freedman ◽  
...  

6531 Background: Annual mammography is recommended to screen residual breast tissue for new cancers and recurrent disease after treatment for early stage breast cancer. This study aimed to assess mammography rates over time in breast cancer survivors. Methods: We used administrative claims data from a large U.S. commercial insurance database, OptumLabs, to retrospectively identify privately- and Medicare Advantage-insured women with operable breast cancer who had residual breast tissue after definitive breast surgery between 2006 and 2015. We required coverage for at least 13 months following surgery. For each subsequent 13-month time period, we only included women without a loss of coverage, bilateral mastectomy, metastatic breast cancer diagnosis, or non-breast cancer diagnosis. We calculated the proportion of patients who had a mammogram during each 13-month period following breast surgery. We used multivariable logistic regression to test for factors associated with mammography in the first 13 months. Results: The cohort included 26,011 women followed for a median of 2.9 years (IQR 1.9-4.6) after surgery; 63.1% were less than 65 years of age, and 74.4% were white. In their first year of follow-up, 86% underwent mammography, but by year 7, this decreased to 73%. Fewer than 1% underwent MRI instead of mammography. In multivariable analysis, mammograms were less likely during the first year after surgery among women aged < 50 years (odds ratio [OR], 0.7; 95% confidence interval [CI], 0.6 to 0.8), African Americans (OR, 0.7; 95% CI, 0.7 to 0.8), patients who underwent mastectomy (OR, 0.7; 95% CI, 0.6 to 0.7), and patients residing in the Western part of the country (OR, 0.9; 95% CI, 0.7 to 0.9). Those with 1-2 comorbidities were more likely (OR, 1.1; 95% CI 1.1-1.2) than those with none to have a mammogram during that period. Mammography use did not differ significantly by year of diagnosis (2006-2015). Conclusions: Even in an insured cohort, a substantial proportion of breast cancer survivors do not undergo annual surveillance mammography. Mammography use falls as the time from the early stage breast cancer diagnosis increases. Understanding factors associated with lack of mammographic screening may help improve survivorship care.


2020 ◽  
Author(s):  
Elena Tsolaki ◽  
William Doran ◽  
Luca Magnani ◽  
Alessandro Olivo ◽  
Inge K. Herrmann ◽  
...  

The presence of calcification in tumours has been known for decades1. Indeed, calcified breast tissue is a fundamental criterion for early breast cancer diagnosis, indicative of malignancies2, and their appearance is used to distinguish between benign and malignant in breast biopsies3,4. However, an in-depth characterization of the nature and origin of tumour tissue calcification remains elusive5–8. Here, we report the presence of nano and micron-sized spherical particles made of highly crystalline whitlockite that are exclusively found in the arterial wall of malignant invasive tumours. By applying nanoanalytical methods to healthy, benign and malignant tumour breast tissue biopsies from patients, we show that poorly crystalline apatite can be found in all breast tissue samples, whereas spherical crystalline whitlockite particles are present only in invasive cancers, mainly in areas close to the lumen of the arterial wall. Moreover, we demonstrate that the concentration of these spherical crystalline particles increases with the grade of disease, and that their size can be related to tumour type. Therefore, our results not only provide new insight into calcification of tumour tissue, but also enable a precise, yet simple route of breast cancer diagnosis and staging.


2010 ◽  
Author(s):  
Susan Sharp ◽  
Ashleigh Golden ◽  
Cheryl Koopman ◽  
Eric Neri ◽  
David Spiegel

2019 ◽  
Vol 3 (48) ◽  
pp. 7
Author(s):  
Alina Oana Rusu-Moldovan ◽  
Maria Iuliana Gruia ◽  
Dan Mihu

Sign in / Sign up

Export Citation Format

Share Document